Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Dec;86(4):877–888. doi: 10.1111/j.1476-5381.1985.tb11110.x

[14C]-beta-phenethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors.

G Garcha, P R Imrie, E Marley, D V Thomas
PMCID: PMC1916635  PMID: 4075021

Abstract

[14C]-beta-phenethylamine [( 14C]-PEA) was instilled intragastrically, intraduodenally (i.d.) or infused into the portal vein or femoral artery of cats, anaesthetized with chloralose, to investigate its distribution in the body. [14C]-PEA and phenylacetic acid (PAA) accounted for approximately 85% of radioactivity recovered in blood from control cats or those pretreated with deprenyl or mebanazine. Progressively greater portal venous (PV), cranial mesenteric arterial (CMA) and PV-CMA concentrations of PEA and PAA were observed with increase in amount of PEA instilled intraduodenally (i.d.); PAA predominated over PEA, more so in CMA than PV blood. Radioactivity was not recovered from blood following intragastric instillation of PEA. When histamine 1.7 mumol kg-1, i.d., was combined with PEA 1.7 mumol kg-1, i.d., or tyramine 8.5 mumol kg-1, i.d., was combined with PEA 8.5 mumol kg-1, i.d., PV-CMA values for PEA were significantly augmented. Arterial concentrations of PEA were increased 3.5 to 5 fold compared to controls by pretreatment with mebanazine or deprenyl plus clorgyline; arterial concentrations of PAA were reduced. PEA blood concentrations were not significantly altered by clorgyline or deprenyl pretreatment. Infusion of PEA 680, 1020 or 1360 nmol kg-1 min-1 for 20 min into the portal vein raised blood pressure 60 to 100 mmHg (at a PEA concentration of ca, 2 nmol ml-1) but lacked effect on the nictitating membrane despite peak arterial PEA concentrations of 20 nmol ml-1; in cats pretreated with mebanazine or clorgyline plus deprenyl, half-maximum contraction of the nictitating membrane occurred with arterial PEA concentrations of 4.8 to 9 nmol ml-1. In cats pretreated with mebanazine or deprenyl plus clorgyline, half maximum contraction of the nictitating membrane was elicited also by intraduodenal PEA 8.5 mumol kg-1 at arterial PEA concentrations of ca. 2 nmol ml-1, despite lack of effect of PEA 17 mumol kg-1, i.d., in control cats with a peak arterial PEA concentration of 1.8 nmol ml-1. [14C]-PEA and PAA were recovered from liver, kidney, distal small intestine, lung, arterial vessel walls, skeletal muscle, brain, foetus and amniotic liquor, after PEA instilled i.d., overall concentration of PEA exceeding that of PAA except in the kidney. The combined amount of PEA and PAA in kidney was 7 to 20 fold that in other tissues. PEA content of tissues was significantly elevated and that of PAA diminished by pretreatment with deprenyl plus clorgyline, and to a lesser extent after mebanazine.

Full text

PDF
877

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASATOOR A. M., LEVI A. J., MILNE M. D. TRANYLCYPROMINE AND CHEESE. Lancet. 1963 Oct 5;2(7310):733–734. doi: 10.1016/s0140-6736(63)90368-4. [DOI] [PubMed] [Google Scholar]
  2. Blackwell B., Marley E. Interactions of cheese and of its constituents with monoamine oxidase inhibitors. Br J Pharmacol Chemother. 1966 Jan;26(1):120–141. doi: 10.1111/j.1476-5381.1966.tb01816.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohen I., Fischer J. F., Vogel W. H. Physiological disposition of beta-phenylethylamine, 2,4,5-trimethoxyphenylethylamine, 2,3,4,5,6-pentamethoxyphenylethylamine and beta-hydroxymescaline in rat brain, liver and plasma. Psychopharmacologia. 1974 Mar 21;36(1):77–84. doi: 10.1007/BF00441384. [DOI] [PubMed] [Google Scholar]
  4. Dewhurst W. G., Marley E. Action of sympathomimetic and allied amines on the central nervous system of the chicken. Br J Pharmacol Chemother. 1965 Dec;25(3):705–727. doi: 10.1111/j.1476-5381.1965.tb01794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dial E. J., Clarke D. E. Phenylethylamine--deamination by multiple types of monoamine oxidase. Biochem Pharmacol. 1978;27(19):2374–2375. doi: 10.1016/0006-2952(78)90148-x. [DOI] [PubMed] [Google Scholar]
  6. Garcha G., Imrie P. R., Marley E., Thomas D. V. Distribution and effects of intestinally administered [14C]-tyramine in cats, modified by monoamine oxidase inhibitors. J Psychiatr Res. 1982;17(1):75–92. doi: 10.1016/0022-3956(82)90035-8. [DOI] [PubMed] [Google Scholar]
  7. Imrie P. R., Marley E., Thomas D. V. Metabolism and distribution of exogenous histamine in cats. Br J Pharmacol. 1978 Sep;64(1):109–122. doi: 10.1111/j.1476-5381.1978.tb08647.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lyles G. A., Callingham B. A. Evidence for a clorgyline-resistant monoamine metabolizing activity in the rat heart. J Pharm Pharmacol. 1975 Sep;27(9):628–691. [PubMed] [Google Scholar]
  9. MACINTOSH F. C., PATON W. D. M. The liberation of histamine by certain organic bases. J Physiol. 1949 Aug;109(1-2):190–219. doi: 10.1113/jphysiol.1949.sp004385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Marley E., Blackwell B. Interactions of monoamine oxidase inhibitors, amines, and foodstuffs. Adv Pharmacol Chemother. 1970;8:185–349. doi: 10.1016/s1054-3589(08)60597-9. [DOI] [PubMed] [Google Scholar]
  11. Neff N. H., Yang H. Y. Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 1974 Jun 1;14(11):2061–2074. doi: 10.1016/0024-3205(74)90089-7. [DOI] [PubMed] [Google Scholar]
  12. PATON W. D. The release of histamine. Prog Allergy. 1958;5:79–148. [PubMed] [Google Scholar]
  13. Sandler M., Youdim M. B., Hanington E. A phenylethylamine oxidising defect in migraine. Nature. 1974 Jul 26;250(464):335–337. doi: 10.1038/250335a0. [DOI] [PubMed] [Google Scholar]
  14. Shannon H. E., Cone E. J., Yousefnejad D. Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog. J Pharmacol Exp Ther. 1982 Oct;223(1):190–196. [PubMed] [Google Scholar]
  15. Squires R. F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol. 1972;5:355–370. [PubMed] [Google Scholar]
  16. Tacker M., McIsaac W. M., Creaven P. J. Metabolism of tyramine-1-14C by the rat. Biochem Pharmacol. 1970 Oct;19(10):2763–2773. doi: 10.1016/0006-2952(70)90103-6. [DOI] [PubMed] [Google Scholar]
  17. Thomas D. V., Marley E. Separation of radioactive histamine and some of its metabolites by one-dimensional paper chromatography. J Chromatogr. 1978 Feb 1;148(2):477–483. doi: 10.1016/s0021-9673(00)85308-x. [DOI] [PubMed] [Google Scholar]
  18. Yang H. Y., Neff N. H. Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther. 1973 Nov;187(2):365–371. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES